Johnson & Johnson's Q2 Earnings: Stability, Innovation, and Dividend Appeal

# Johnson & Johnson Stock Analysis: Earnings Preview, Analyst Ratings & Investment Outlook Explore the latest financial analysis of Johnson & Johnson (JNJ) ahead of its July 16th earnings report. Currently trading at $156.90, this episode examines analyst expectations of $2.68 EPS on $22 billion revenue, institutional investor movements, and JNJ's innovation strategy in Innovative Medicine and MedTech divisions. Learn why despite mixed sentiment, most analysts maintain buy/hold ratings with price targets suggesting 8-10% upside potential. Discover how JNJ's consistent 3%+ dividend yield, strong free cash flow, and strategic acquisitions in neuroscience position this healthcare giant as a stable income investment despite recent sector-specific challenges. Perfect for dividend investors seeking lower-volatility stocks with reliable growth potential. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.